X

Trial Profile

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denifanstat (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors 3-V Biosciences; Sagimet Biosciences

Most Recent Events

05 Aug 2019 According to a 3-V Biosciences media release, the company has changed its name to Sagimet Biosciences.
11 Aug 2017 Status changed from active, no longer recruiting to completed.
31 Mar 2017 According to a 3-V Biosciences media release, the company will present data from this trial at the AACR annual meeting in Washington, D.C.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com